Patents by Inventor Christopher L. Parks

Christopher L. Parks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030206925
    Abstract: Modified Morbilliviruses having at least one mutation in the region corresponding to amino acids 112-134 of the measles virus V protein are described, wherein one or both of amino acids 113 or 114 is mutated. Such modified Morbilliviruses exhibit reduced repression of gene expression. Additional mutations or deletions in other regions of the genome may be included, including in the carboxy-terminal region.
    Type: Application
    Filed: December 16, 2002
    Publication date: November 6, 2003
    Inventor: Christopher L. Parks
  • Publication number: 20030129729
    Abstract: This invention relates to improved methods for producing nonsegmented, negative-sense, single-stranded RNA viruses of the Order designated Mononegavirales virus, including embodiments relating to methods of producing such viruses as attenuated and/or infectious viruses, such as Measles virus (MV) and respiratory syncytial virus (RSV).
    Type: Application
    Filed: October 1, 2002
    Publication date: July 10, 2003
    Applicant: Wyeth
    Inventors: Christopher L. Parks, Mohinderjit S. Sidhu, Stephen A. Udem, Gerald R. Kovacs
  • Publication number: 20020055173
    Abstract: Multiple binding sites for the transcription factors MAZ and Sp1 within the adenovirus type 5 major late promoter have been identified by DNase I protection studies. In the proximal region of the promoter, both MAZ and Sp1 interact with GC-rich sequences flanking the TATA box. Two MAZ binding sites are centered at −18 and −36 relative to the transcriptional initiation site. Sp1 bound only to the −18 GC-rich sequence. Several sites of interaction were also evident in the distal region of the promoter. Both MAZ and Sp1 interacted with a sequence centered at −166, and MAZ bound weakly to an additional site centered at −130. Over expression of MAZ or Sp1 activated expression from the major late promoter in transient expression assays.
    Type: Application
    Filed: May 21, 2001
    Publication date: May 9, 2002
    Inventors: Christopher L. Parks, Thomas Shenk